AbbVie will acquire neuroscience-drug maker Cerevel Therapeutics Holdings for $45 a share, giving the company an equity value of about $8.7 billion. The deal is AbbVie’s second major acquisition ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Let's decide whether AbbVie is a buy. In the pharmaceutical business ... and $8.7 billion for Cerevel Therapeutics. The company's ratio of debt to EBITDA (earnings before interest, taxes ...

Let's decide whether AbbVie is a buy. In the pharmaceutical business ... and $8.7 billion for Cerevel Therapeutics.